Inavolisib Side Effects
Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.
Applies to inavolisib: oral tablets.
Side effects include:
Most common adverse reactions (≥20%), including laboratory abnormalities: decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased ALT, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, headache.
For healthcare professionals
Applies to inavolisib: oral tablet.
General adverse events
The most common adverse reactions occurring in at least 20% of patients included decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased ALT, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, and headache.[Ref]
Dermatologic
- Very common (10% or more): Rash (26%), alopecia (19%), dry skin/fissures/xerosis/xeroderma (13%)
Endocrine
- Very common (10% or more): Increased fasting glucose levels (85%)
Gastrointestinal
- Very common (10% or more): Stomatitis (51%), diarrhea (48%), nausea (28%), increased lipase (16%), vomiting (15%)
- Frequency not reported: Abdominal pain, dysgeusia, dyspepsia
Stomatitis included aphthous ulcer, glossitis, glossodynia, lip ulceration, mouth ulceration, and mucosal inflammation.
Hematologic
- Very common (10% or more): Decreased total and absolute neutrophils (95%), decreased hemoglobin (88%), decreased platelets (84%), decreased absolute lymphocytes (72%)
Hepatic
- Very common (10% or more): Increased ALT (34%)
Metabolic
- Very common (10% or more): Decreased appetite (24%), decreased calcium (42%), decreased potassium (38%), decreased sodium (28%), decreased magnesium (27%)
Nervous system
- Very common (10% or more): Headache (22%)
Ocular
- Frequency not reported: Dry eye
Other
- Very common (10% or more): Fatigue (38%), COVID-19 infection (23%), decreased weight (17%)
Renal
- Very common (10% or more): Increased creatinine (38%), urinary tract infection (15%)
See also:
References
1. (2024) "Product Information. Itovebi (inavolisib)." Genentech
More about inavolisib
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: PI3K inhibitors
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Inavolisib side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
